Pfizer announces FDA and EMA acceptance of etrasimod regulatory submissions for ulcerative colitis

PfizerPfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for etrasimod for individuals living with moderately-to-severely active ulcerative colitis (UC). The FDA's decision is expected in the second half of 2023. The European Medicines Agency (EMA) has also accepted the Marketing Authorization Application (MAA) for etrasimod in the same patient population with the decision anticipated in the first half of 2024.


from Breaking World Pharma News https://ift.tt/jzboL9i

Comments